PURLS / PEER REVIEWED

Can Vitamin D Prevent Acute Respiratory Infections?

Author and Disclosure Information

 

References

WHAT’S NEW

A more accurate snapshot

Previous studies of vitamin D and respiratory tract infections were mostly observational in nature. Those that were RCTs used variable doses of vitamin D, had variable baseline 25(OH)D levels, and employed various methods to monitor ARTI symptoms/incidence.5-8 This is the first systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials with supplementation using vitamin D3 or D2 that used individual participant-level data, which gives a more accurate estimate of outcomes when compared with traditional meta-analyses.

CAVEATS

Only the most deficient benefit?

Vitamin D supplementation was safe and protected against ARTIs overall, but the greatest effect was noted in those who were most severely vitamin D deficient (those with circulating 25(OH)D levels < 10 ng/mL [NNT, 4] and those with circulating 25(OH)D levels 10-28 ng/mL [NNT, 15]). There was no demonstrable effect once circulating 25(OH)D levels reached 30 ng/mL.

CHALLENGES TO IMPLEMENTATION

Breaking tradition

The study found that both daily and weekly doses of vitamin D were effective in reducing the incidence of ARTIs. However, the doses studied were much lower than those commonly used (10,000 to 50,000 IU bolus), which were ineffective in reducing ARTIs in this meta-analysis. Changing from bolus dosing may prove challenging, as it is an ingrained practice for many providers.

In addition, the authors of the study suggest that one way to provide this level of vitamin D is through food fortification. But this method is often complicated by emotional and/or political issues that could thwart implementation.

ACKNOWLEDGEMENT

The PURLs Surveillance System was supported in part by Grant Number UL1RR024999 from the National Center For Research Resources, a Clinical Translational Science Award to the University of Chicago. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center For Research Resources or the National Institutes of Health.

Copyright © 2019. The Family Physicians Inquiries Network. All rights reserved.

Reprinted with permission from the Family Physicians Inquiries Network and The Journal of Family Practice (2019;68[4]:230-231).

Pages

Recommended Reading

Cardiovascular cost of smoking may last up to 25 years
Clinician Reviews
Impact of climate change on mortality underlined by global study
Clinician Reviews
Vaping illness cases now over 150, CDC says
Clinician Reviews
FUO, pneumonia often distinguishes influenza from RSV in hospitalized young children
Clinician Reviews
Years ago, this doctor linked a mysterious lung disease to vaping
Clinician Reviews
First death from severe lung illness associated with vaping reported in Illinois
Clinician Reviews
Mysterious vaping lung injuries may have flown under regulatory radar
Clinician Reviews
Vaping-related lung disease cases rise, case reporting standardized
Clinician Reviews
Michigan becomes first state to ban flavored e-cigarettes
Clinician Reviews
Less CPAP time linked to exacerbation in COPD/OSA overlap syndrome
Clinician Reviews